Get the Stockscreener App
283.00
0.27%
-0.77
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Cencora Inc stock is traded at $283.00, with a volume of 2.60M.
It is down -0.27% in the last 24 hours and up +3.33% over the past month.
Cencora is one of three domestic leading pharmaceutical wholesalers. It sources and distributes branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. It and McKesson and Cardinal Health constitute over 90% of the us pharmaceutical wholesale industry. Cencora also provides commercialization services for manufacturers of pharmaceuticals and medical devices, global specialty drug logistics (World Courier), and animal health product distribution (MWI Animal Health). Cencora expanded its international presence in 2021 by purchasing Alliance Healthcare, one of the leading drug wholesalers in Europe.
See More
Previous Close:
$283.77
Open:
$285.92
24h Volume:
2.60M
Relative Volume:
1.45
Market Cap:
$56.59B
Revenue:
$310.23B
Net Income/Loss:
$1.69B
P/E Ratio:
32.83
EPS:
8.62
Net Cash Flow:
$3.58B
1W Performance:
-3.12%
1M Performance:
+3.33%
6M Performance:
+13.92%
1Y Performance:
+26.29%
1-Day Range:
$282.81
$289.24
1-Week Range:
$282.81
$309.35
52-Week Range:
$214.77
$309.35
Cencora Inc Stock (COR) Company Profile
Name
Cencora Inc
Sector
Industry
Phone
610-727-7000
Address
1 WEST FIRST AVENUE, CONSHOHOCKEN
Compare COR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
COR
Cencora Inc
|
283.00 | 56.59B | 310.23B | 1.69B | 3.58B | 8.62 |
|
MCK
Mckesson Corporation
|
693.46 | 88.78B | 344.58B | 2.83B | 1.63B | 21.84 |
|
CAH
Cardinal Health Inc
|
148.22 | 35.69B | 222.29B | 1.56B | 2.44B | 6.41 |
|
HSIC
Henry Schein Inc
|
68.64 | 7.95B | 12.50B | 314.00M | 421.00M | 2.44 |
|
OMI
Owens Minor Inc
|
7.01 | 580.18M | 10.42B | -38.77M | 323.54M | -0.51 |
Cencora Inc Stock (COR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-04-24 | Resumed | Mizuho | Outperform |
| Sep-18-24 | Downgrade | BofA Securities | Buy → Neutral |
| Feb-26-24 | Initiated | Leerink Partners | Outperform |
| Jan-03-24 | Initiated | Barclays | Overweight |
| Dec-14-23 | Initiated | Wells Fargo | Equal Weight |
| Mar-31-23 | Initiated | Citigroup | Buy |
| Jan-31-23 | Resumed | Evercore ISI | Outperform |
| Oct-11-22 | Upgrade | BofA Securities | Neutral → Buy |
| Aug-22-22 | Resumed | Morgan Stanley | Equal-Weight |
| Jul-11-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Jun-07-22 | Upgrade | Deutsche Bank | Hold → Buy |
| May-26-22 | Upgrade | Barclays | Equal Weight → Overweight |
| Apr-12-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-01-22 | Resumed | Credit Suisse | Outperform |
| Mar-12-21 | Resumed | Evercore ISI | In-line |
| Feb-04-21 | Upgrade | Evercore ISI | In-line → Outperform |
| Feb-02-21 | Upgrade | Cowen | Market Perform → Outperform |
| Jan-06-21 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-06-21 | Upgrade | Credit Suisse | Neutral → Outperform |
| Dec-10-20 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| Dec-03-20 | Initiated | Mizuho | Neutral |
| Aug-06-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jul-15-20 | Initiated | Barclays | Underweight |
| Jun-15-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Apr-23-20 | Resumed | Credit Suisse | Outperform |
| Apr-16-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Apr-13-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Apr-01-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Mar-17-20 | Upgrade | Citigroup | Neutral → Buy |
| Feb-11-20 | Downgrade | BofA/Merrill | Buy → Underperform |
| Feb-07-20 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Sep-12-19 | Initiated | Deutsche Bank | Hold |
| Jul-10-19 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| Apr-11-19 | Initiated | Guggenheim | Buy |
| Apr-10-19 | Downgrade | BofA/Merrill | Buy → Underperform |
| Apr-10-19 | Downgrade | Evercore ISI | Outperform → In-line |
| Feb-11-19 | Downgrade | JP Morgan | Neutral → Underweight |
| Jan-17-19 | Initiated | UBS | Buy |
| Dec-10-18 | Downgrade | Jefferies | Buy → Hold |
| Oct-26-18 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Sep-20-18 | Initiated | Berenberg | Buy |
| Jul-17-18 | Resumed | Stifel | Hold |
| Apr-09-18 | Initiated | MoffettNathanson | Buy |
| Mar-12-18 | Upgrade | KeyBanc Capital Mkts | Sector Weight → Overweight |
| Mar-12-18 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Sep-25-17 | Initiated | JP Morgan | Neutral |
| Sep-22-17 | Initiated | William Blair | Outperform |
View All
Cencora Inc Stock (COR) Latest News
Cencora increases FY2025 EPS guidance to $15.70-$15.95 amid specialty growth - MSN
Here's Why Cencora (COR) is a Strong Momentum Stock - Yahoo Finance
Cencora Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Citigroup Maintains Buy Rating and Raises Price Target for Cencora (COR) | COR Stock News - GuruFocus
Cencora (COR) Reaches New Heights with Increased Price Target | COR Stock News - GuruFocus
Cencora, Inc. (COR) Hits Fresh High: Is There Still Room to Run? - Yahoo Finance
Cencora (COR) Receives Increased Price Target from Baird Analyst | COR Stock News - GuruFocus
Cencora (COR) Price Target Increased as U.S. Results Impress | COR Stock News - GuruFocus
Cencora Inc (COR) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and Raised Full-Year ... - Yahoo Finance
Cencora Earnings: Strong Utilization and GLP-1s Maintain Growth Momentum and RCA Expands Margins - Morningstar
Cencora Inc (COR) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and Raised Full-Year Guidance - GuruFocus
Cencora, Inc. Reports Strong Q2 2025 Results - TipRanks
Earnings call transcript: Cencora Inc Q1 2025 beats earnings expectations, stock surges - Investing.com Nigeria
Cencora’s Earnings Call: Strong Growth Amid Challenges - TipRanks
Earnings call transcript: Cencora Inc Q1 2025 beats earnings expectations, stock surges By Investing.com - Investing.com South Africa
Cencora Inc. stock outperforms competitors on strong trading day - MarketWatch
Cencora Q2 2025 slides: adjusted EPS jumps 16.3%, guidance raised By Investing.com - Investing.com South Africa
Cencora Enjoys Strong Momentum From GLP-1s, Healthy Utilization Trends, and Growing Specialty Assets - Morningstar
Cencora: Fiscal Q2 Earnings Snapshot - MySA
Cencora (NYSE:COR) Sees Strong Q2 Earnings Surge; Declares US$0.55 Dividend - simplywall.st
Jim Cramer Rediscovers Love For Magnificent 7 & Discusses These 11 Stocks - Insider Monkey
Cencora's Boosts Annual Forecast On Strong Demand For Weight Loss Drugs, Specialty Products Despite Mixed Q2 Earnings - Benzinga
Jim Cramer on Cencora, Inc. (COR): ‘Middleman Money Machine Silences the Doubters’ - MSN
Cencora, Inc. SEC 10-Q Report - TradingView
COR Q2 Earnings & Revenues Beat Estimates, '25 EPS Guidance Raised - Yahoo
Transcript : Cencora, Inc., Q2 2025 Earnings Call, May 07, 2025 - marketscreener.com
Cencora Inc (COR) Sees Significant Stock Price Increase | COR Stock News - GuruFocus
Cencora raises annual profit forecast on strong demand for specialty drugs - Reuters
Cencora, Inc. 2025 Q2ResultsEarnings Call Presentation (NYSE:COR) - Seeking Alpha
Cencora Ups Profit Forecast Thanks To Drug Demand - Finimize
Cencora Exceeds EPS Estimates, Achieves Revenue Goals in Q1 2025News and Statistics - IndexBox
Cencora Q2 2025 slides: adjusted EPS jumps 16.3%, guidance raised - Investing.com
Cencora (COR) Misses Q2 Revenue Expectations but Highlights Strong Market Role | COR Stock News - GuruFocus
Cencora (COR) Updates FY25 Guidance with Focus on U.S. Earnings Growth | COR Stock News - GuruFocus
Cencora Reports Strong Q2 2025 Financial Results - TipRanks
Cencora Inc (COR) Q2 2025 Earnings: EPS Surpasses Estimates at $3.68, Revenue Falls Short at $75.5 Billion - GuruFocus
Cencora Inc earnings beat by $0.36, revenue topped estimates - Investing.com South Africa
Cencora Reports Fiscal 2025 Second Quarter Results | COR Stock News - GuruFocus
Earnings Flash (COR) CENCORA Posts Q2 Adjusted EPS $4.42, vs. FactSet Est of $4.11 - marketscreener.com
Cencora, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2025 - marketscreener.com
Unveiling Cencora (COR) Q2 Outlook: Wall Street Estimates for Key Metrics - MSN
Will Speciality and GLP-1 Drugs Help COR Beat Q2 Earnings Estimates? - TradingView
Those who invested in Cencora (NYSE:COR) five years ago are up 253% - simplywall.st
Cencora to support US launch of Neurotech’s cell therapy, ENCELTO - Ophthalmology Times
Cencora (COR) Earnings Expected to Grow: Should You Buy? - Yahoo
UBS Adjusts Price Target on Cencora to $335 From $298, Maintains Buy Rating - marketscreener.com
Cencora, Inc. : The resistance should give in - marketscreener.com
Earnings Preview: What To Expect From Cencora's Report - MSN
Cencora (COR) Surged on Strong Returns - Insider Monkey
Here's How Much You Would Have Made Owning Cencora Stock In The Last 5 YearsCencora (NYSE:COR) - Benzinga
Cencora Inc Stock (COR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.65%
0.36%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):